Program
Hall A
08:00-09:00
Registration and refreshments
09:00-11:00
Congress opening
Ivan Marković, Nada Santrač, Special guests
.
KEY NOTE LECTURE
Economic perspective of cancer treatments – cost or investment?
Thomas Hofmarcher (Sweden)
.
KEY NOTE LECTURE
New Suggested National Swedish Cancer Strategy
Mef Nilbert (Sweden)
.
HOT TOPIC
National Guidelines for Diagnostics and Treatment of Breast Cancer – where are we now and what are the future perspectives?
Ferenc Vicko
11:00-11:45
Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration – part 1: Diagnostics
Moderators: Mirjan Nadrljanski, Nada Santrač
11:00-11:20
Optimizing Axillary Assessment: Imaging Strategies for Accurate Nodal Staging in Early Breast Cancer
Mirjan Nadrljanski
11:20-11:45
Panel discussion
Marijana Milović Kovačević, Merima Goran, Olivera Ivanov, Dejan Dimitrijević
11:45-12:00
Coffee break
12:00-12:45
Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration – part 2: Surgery
Moderators: Ivan Marković, Nada Santrač
12:00-12:20
De-escalating Axillary Surgery: Balancing Oncologic Safety and Quality of Life in Early Breast Cancer
David Pinto
12:20-12:45
Panel discussion
Ferenc Vicko, Marko Buta, Marko Spasić
12:45-13:15
Sponsored symposium
ROCHE
Integration of Genomic Medicine into the Serbian Healthcare System
Moderator: Branka Zukić
From Pilot Project to Systemic Transformation of the Healthcare
Ecosystem –
Branka Zukić, Milica Kontić
13:15-14:15
Lunch
14:15-15:00
Shaping the Future of Early Breast Cancer Treatment: Precision, De- escalation, and Integration – part 3: Systemic treatment
Moderators: Marijana Milović Kovačević, Milana Matović
14:15-14:30
Beyond positive axillary lymph nodes – when do we go bigger in systemic treatments?
Marijana Milović Kovačević
14:30-15:00
Panel discussion
Nada Santrač, Gorana Matovina Brko, Tatjana Ivković Kapicl
15:00-16:00
Sponsored symposium
Novartis
Opening and Introduction: Setting the Stage and Addressing
Unmet Need in HR+/HER2-eBC
Moderator: Ivana Božović Spasojević
NATALEE 5-year outcomes - Lazar Popović
High risk N+ patients: Evaluating treatment efficacy - Marijana Milović Kovačević
N0 NATALEE data: Why is it important to treat N0 HR+/HER2-
EBC at high risk of recurrence – Dejan Jurić
Ribociklib: Unique characteristics in EBC therapy - Ana Cvetanović
Discussion
16:00-16:15
Coffee break
16:15-16:50
Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration – part 4: Radiotherapy
Moderators: Jasmina Mladenović, Simonida Bobić
16:15-16:30
Omission or de-escalation of radiotherapy in early breast cancer conservative treatment
Olivera Ivanov
16:30-16:50
Panel discussion
Aleksandar Ranković, Neda Milosavljević
16:50-17:55
Shaping the Future of Early Breast Cancer Treatment: Precision, De-escalation, and Integration – part 5: Survivorship
Moderators: Nada Santrač, Marijana Milović Kovačević
16:50-17:10
Life After Breast Cancer: Redefining Survivorship in the Era of Precision Medicine
Antonio Di Meglio (France)
17:10-17:25
Panel discussion
Joseph Gligorov (France), Ivan Marković, Tanja Španić EUROPA DONNA (Slovenia), Nina Kovačević, Ana Jovićević
17:25-17:40
Early Integrated Rehabilitation for Genitourinary Syndrome of Menopause in Breast Cancer Patients in Slovenia
Nina Kovačević (Slovenia)
17:40-17:55
Panel discussion
Antonio Di Meglio (France), Joseph Gligorov (France), Tanja Španić EUROPA DONNA (Slovenia), Ana Jovićević
17:55-18:00
Break
18:00-19:15
20 years of Serbian Society of Medical Oncology (UMOS)
Moderators: Zoran Tomašević, Nenad Milanović, Siniša Radulović, Davorin Radosavljević
18:00-18:10
Why do we need UMOS?
Davorin Radosavljević
18:10-18:20
Why is UMOS necessary for researchers?
Milena Čavić
18:20-18:35
The Long Road to Personalized Oncology: Will the Next 20 Years Follow the Same Path?
Lazar Popović
18:35-19:15
Panel discussion: Between ESMO, NCCN i RFHI – what are the biggest achievements of Serbian oncology?
Moderator: Ivana Božović Spasojević
Panelists: Zoran Andrić, Suzana Matković, Marijana Milović Kovačević, Jelena Spasić, Ljiljana Stamatović, Ana Cvetanović
19:15-19:30
Break
19:30
Welcome cocktail (Atrium)
Hall B
11:00-12:00
HOT TOPICS IN LUNG CANCER 1
Big things in small-cell
Moderator: Bojan Zarić
11:00-11:20
New era of SCLC treatment – an orphan no more?
Carles Escriu (UK)
11:20-11:40
Challenges of radiotherapy in the new era of SCLC treatment
Tatjana Arsenijević
11:40-12:00
Panel discussion
Marina Cekić, Katja Mohorčić (Slovenia), Tatjana Bošković, Carles Escriu (UK)
12:00-12:45
Sponsored symposium
ROCHE
Mission for brightness in SCLC
Moderator: Jelena Spasić
SCENE of local clinical practice - Jelena Spasić
Navigating to the NorthStar in SCLC galaxy – Carles Escriu
Spotlight on long term responders - Zoran Andrić
New horizons in SCLC treatment landscape - Bojan ZarićMission for brightness in SCLC
12:45-13:00
Coffee break
13:00-14:10
HOT TOPICS IN LUNG CANCER 2
Evolving treatment paradigms in early stage disease
Moderator: Jelena Spasić
13:00-13:15
IO in early stage non-oncogene addicted NSCLC: neoadjuvant or perioperative, is there a standard?
Bojan Zarić
13:15-13:30
Early stage oncogene-addicted NSCLC – moving towards a new standard of care?
Daliborka Bursać
13:30-13:45
ctDNA and MRD in early-stage NSCLC: ready for prime-time?
Feđa Đorđević
13:45-14:10
Panel discussion
Bojan Zarić, Nebojša Marić, Dejan Stojiljković, Tatjana Arsenijević, Natalija Samardžić
14:10-15:00
Lunch
15:00-15:30
Sponsored symposium
MSD
Where science meets practice: Keytruda® (pembrolizumab) case
highlights from young lung cancer physicians
Moderator: Jelena Spasić
Panelists: Katarina Ljujić, Nikola Marić, Jelena Petkov, Jelena Mikov
15:30-16:40
HOT TOPICS IN LUNG CANCER 3
Evolving treatment paradigms in early stage disease
Moderator: Bojan Zarić
15:30-15:45
Unresectable NSCLC – what is new?
Aleksandar Stepanović
15:45-16:00
Toxicity and quality of life when using IO in early stage NSCLC: issues for survivorship
Jelena Spasić
16:00-16:15
Using IO in metastatic disease after treatment of early stage: do we have enough data
Katja Mohorčić (Slovenia)
16:15-16:40
Panel discussion
Feđa Đorđević, Marta Velinović, Daliborka Bursać, Goran Stojanović
16:40-17:00
Coffee break
17:00-17:30
Sponsored symposium
Pfizer
Expert Panel Meeting - From principles to practice: Enhancing the
patient experience in ALK+ aNSCLC
Moderator: Bojan Zarić
Panelists: Natalija Samardžić, Marija Peulić
17:30-18:00
Sponsored symposium
Johnson&Johnson
mNSCLC with EGFRm: Rybrevant® (amivantamab) as an answer
to the unmet need
mNSCLC - Diagnostic challenges and therapeutic gaps - Goran
Stojanović
Clinical significance of Rybrevant ® in NSCLC with EGFR exon20
insertion - Biljana Filipović
Amivantamab with chemotherapy: A new chance after osimertinib
- Zoran Andrić
Discussion
18:00-18:30
Sponsored symposium
PharmaSwiss
Antiemetic strategy in modern oncology: Adapting therapy to new
protocols
Moderator: Snežana Bošnjak
CINV- Recommendations for antiemetics use in MASCC ESMO
2023 guideline - Jelena Dimitrijević
Prevention of nausea and vomiting induced by ADCs - Snežana
Bošnjak
Q&A
19:30
Welcome cocktail (Atrium)
Hall A
08:00-09:00
Oral presentations of selected abstracts
09:00-09:40
KEY NOTE LECTURE
Future of Oncology
Charles Balch (USA)
09:40-10:30
Pregnancy after breast cancer diagnosis – outpatients oncofertility clinic IORS
Moderators: Nataša Lazin, Snežana Šušnjar
09:40-09:55
Support for young women with breast cancer who desire having children – our experience
Nataša Lazin
09:55-10:10
Safety of temporarily interrupting endocrine therapy for pregnancy – what have we learnt from ETOP-IBCSG Positive study
Snežana Šušnjar
10:10-10:30
Discussion
10:30-10:45
Coffee Break
10:45-12:15
Metastatic Breast Cancer 1
The Art of Sequencing: Clinical and Scientific Perspectives in HR+
Metastatic Breast Cancer
Moderators: Lazar Popović, Ivana Božović Spasojević
10:45-11:00
Refining Treatment Strategies: Targeted Therapies in HR+/HER2– Metastatic Breast Cancer
Joseph Gligorov (France)
11:00-11:15
Discussion
11:15-11:30
Decoding the Genome: Precision Insights in HR+/HER2– Metastatic Breast Cancer
Dejan Jurić (USA)
11:30-11:45
Discussion
11:45-12:00
PARP Inhibitors and beyond in the treatment of Metastatic HR+ Breast Cancer with BRCA mutation
Assia Konsoulova (Bulgaria)
12:00-12:15
Discussion
12:15-13:00
Sponsored symposium
ROCHE
A commitment to the future – Tailoring Care for HR+ metastatic
breast cancer
Moderator: Ivana Božović Spasojević
Redefining hope: Showing the unmet need in HR+ metastatic
breast cancer - Ana Cvetanović
PI3Ki: Continued efforts are showing success - Dejan Jurić
Current guidelines in managing patients with HR+/HER2- mBC –
Ivana Božović Spasojević
13:00-13:10
Coffee Break
13:10-13:55
Sponsored symposium
PFIZER
One day on the Clinic: Navigating Clinical Scenarios to
Individualize Care in HR+/HER2-mBC
Moderator: Lazar Popović
Panelists: Ivana Božović Spasojević, Gorana Matovina Brko,
Marija Andrijić
14:00-15:00
Lunch
15:00-16:00
Metastatic Breast Cancer 2
Redefining HER2 Negativity: New Insights, New Targets
Moderators: Marijana Milović Kovačević, Vladimir Todorović
15:00-15:15
HER2 low and ultra-low expression – high expectations and ultra-high standards
Svitlana Bachurska (Bulgaria)
15:15-15:25
Discussion
Tatjana Kapicl, Duško Dunđerović, Ivana Minić
15:25-15:40
New treatment strategies with ADCs in HR+/HER2- metastatic breast cancer
Ana Cvetanović
15:40-16:00
Discussion
Svitlana Bachurska (Bulgaria), Ivana Minić
16:00-17:00
Sponsored symposium
AstraZeneca
Leading with Purpose: Enhertu Across the HER2 Spectrum in
mBC. One therapy. One vision.
Moderator: Marijana Milović Kovačević
Speakers: Lazar Popović, Tatjana Ivković Kapicl, Ana Cvetanović, Ivana Božović Spasojević
17:00-17:45
Sponsored symposium
Eli Lilly
Verzenios is the only CDK4/6 inhibitor with a proven overall
survival benefit in the curative setting and 2 years of treatment
Moderator: Ivana Božović Spasojević
Identifying and acting on High-Risk of recurrence in patients with
HR+, HER2-EBC with nodal involvement - Ana Cvetanović
Verzenios delivers sustained IDFS benefit and OS benefit with 2
years of treatment - Lazar Popović
17:45-18:00
Coffee Break
18:00-18:30
Hematological malignancies 1
Multiple myeloma: where are we now?
Moderators: Mila Purić, Jelena Bila
18:00-18:20
The state-of-the-art in multiple myeloma treatment
Jelena Bila
18:20-18:30
Panel discussion
Jelena Bila, Mila Purić, Nada Vlaisavljević
18:30-19:10
Hematological malignancies 2
Lymphoma highlights
Moderator: Mila Purić
18:30-18:40
Novelties in follicular lymphoma therapy
Maja Popović
18:40-18:50
Novelties in the therapy of diffuse B large cell lymphoma
Mila Purić
18:50-19:00
CART in the treatment of follicular and diffuse B large cell lymphoma
Ivan Petković
19:00-19:10
Panel discussion
Maja Popović, Ivan Petković, Dušan Ristić, Mila Purić
Hall B
08:00-09:00
Oral presentations of selected abstracts
09:00-09:30
Break
09:30-10:15
Hepatocellular carcinoma
Moderators: Marija Ristić
09:30-09:45
Imaging diagnostics of HCC: is biopsy necessary?
Dragan Vasin
09:45-10:00
Systemic treatment of advanced HCC
Ivan Nikolić
10:00-10:15
Panel discussion
Vladimir Cvetić, Miljana Džunić, Nenad Mijalković
10:15-11:15
Sponsored symposium
AstraZeneca
IMFINZI Across the Cancer Continuum
Moderator: Lazar Popović
Panelists: Bojan Zarić, Marijana Milovič Kovačević, Suzana
Matković, Feđa Đorđević
11:15-11:30
Coffee Break
11:30-12:30
Cholangiocellular carcinoma
Moderator: Srđan Nikolić
11:30-11:55
Challenges and novelties in diagnostics of cholangiocellular carcinoma
Jelena Kovač
11:55-12:10
Cholangiocellular carcinoma in the era of targeted treatments
Nebojša Manojlović
12:10-12:30
Panel discussion
Zoran Andrić, Nataša Prvulović Bunović, Neda Nikolić, Radmila Janković
12:30-13:20
Metastatic disease
Moderator: Marija Ristić
12:30-12:42
Evolving treatment of metastatic pancreatic cancer
Marina Marković
12:42-12:54
SBRT of liver metastases
Srđan Milanović
12:54-13:06
ALPPS Procedure in the Management of Borderline Resectable Liver Lesions
Vladimir Jokić
13:06-13:20
Panel discussion
Mlađan Protić, Sanja Kostić, Biljana Šeha
13:20-14:15
Lunch
14:15-15:00
Sponsored symposium
Amicus
Optimizing Outcomes in mCRC: Evidence-Based Insights on
Vectibix
Understanding Metastatic Colorectal Cancer: Challenges and
Advances - Ivan Nikolić
Optimizing Treatment of mCRC with Vectibix - Zafir Murtezani
Clinical Insights on Vectibix: Evidence from the PARADIGM
Trial - Nenad Mijalković
Managing Adverse Effects Associated with Anti-EGFR Treatment
- Miljana Džunić
15:00-16:00
Colorectal Cancer
Moderators: Dragan Radovanović, Marko Dožić
15:00-15:10
Neoadjuvant Approach in Locally Advanced Rectal Cancer: Clinical Standards and the Potential Role of Liquid Biopsy
Mladen Marinković
15:10-15:25
Modern Concept of CRC Treatment – Evolution of the Continuum
Marija Ristić
15:25-15:40
Cytoreductive Surgery and HIPEC in Colorectal Cancer: Evolving Evidence and Emerging Insights
Milan Kocić
15:40-16:00
Panel discussion
Miljan Ćeranić, Saša Jungić, Srđan Nikolić
16:00-16:10
Coffee break
16:10-16:55
Sponsored symposium
Takeda
Fruquintinib: Advancing the Treatment of mCRC
Moderator: Zoran Andrić
Zoran Andrić - Unmet needs in later lines of mCRC treatment
Ivan Nikolić - FRESCO and FRESCO-2: the path to a new
therapeutic option
Marija Ristić - Sequencing strategy in later lines of treatment for
patients with mCRC in Serbia
Nenad Mijalković - A new therapeutic option: patient selection,
timing, and rationale
16:55-17:00
Break
17:00-17:30
Sponsored symposium
Servier
Shaping the Future of Gastrointestinal Cancer Treatment
Moderator: Zoran Andrić
Welcome and Introduction - Zoran Andrić
Advances in the Treatment of Metastatic Colorectal Cancer:
Optimization of Treatment Options - Neda Nikolić
Latest Advances in the Treatment of Metastatic Pancreatic
Cancer: Improving Treatment Practice - Bogdan Bogdanović
Panel Discussion: all participants
Concluding Remarks - Zoran Andrić
17:30-18:00
Sponsored symposium
Novartis
Castration-resistant Prostate Cancer - Integrating Nuclear
Medicine and Oncology perspectives
Marina Krneta Popović, Suzana Matković
18:00-18:15
Sponsored symposium
Merck
Advancements in Therapeutic Strategies for mCRC: Results from Two Phase III Studies
Marija Ristić
18:15-18:30
Break
18:30-20:00
19th PATIENTS’ FORUM
Moderators: Svetlana Berat, Ana Jovićević, Dragana Jovićević
18:30-18:50
Empathy and information - pillars of quality communication in healthcare
Sara Bojanić
18:50-19:10
Return to work after breast cancer treatment - the voice of a female patient from Serbia
Mirjana Branković Magić
19:10-19:30
Treatment of breast cancer in pregnancy
Snežana Šušnjar
19:30-20:00
Q&A
Hall A
08:00-09:00
Oral presentations of selected abstracts
09:00-09:30
KEY NOTE LECTURE
Lifetime journey and paradigm shift in
breast cancer understanding and
treatment
Alberto Costa, ESO (Italy)
09:30-10:30
Special panel
Innovating together: when research meets clinical practice
Moderator: Branka Zukić
.
Panel discussion
Marijana Milović Kovačević, Miljana Tanić, Jadranka Mirković
10:30-10:40
Coffee break
10:40-11:35
Scientific projects in Serbia
Moderators: Ivana Božović Spasojević, Radmila Janković
10:40-10:55
2023-2026: Detection and quantification of residual disease in patients with high-risk and advanced melanoma as a marker of therapy response and prognosis (ReDiMEL); PRIZMA; Fond za nauku Republike Srbije (Beograd)
Lidija Kandolf
10:55-11:10
2023-2026: Advancing REversible immunocapture toward SCALablE EV
purification (RESCALE-EV); PRIZMA;
Fond za nauku Republike Srbije (Beograd)
2025-2028: EXPANDing the value of
Extracellular Vesicles as carriers of
biomarker and therapy in precision
healthcare (EXPAND-EV); Horizont
Evropa, MSCA Staff Exchange; Evropska
lecture komisija (Brisel, Belgija)
Milica Popović
11:10-11:25
MiNe2Brain, Development of an innovative platform consisting of lipid- polymer hybrid nanoparticles and microneedles for targeted brain delivery of novel GABAkines favored by reverse transport; DIJASPORA 2023; Fond za nauku Republike Srbije (Beograd)
Miroslav Savić
11:25-11:35
Discussion
11:35-12:25
Special panel
Artificial intelligence: reshaping the landscape and horizons of oncology
Moderators: Mirjan Nadrljanski, Nada Santrač
11:35-11:50
AI in screening
Mirjan Nadrljanski
11:50-12:10
AI in surgical oncology
Pedro Gouveia (Portugal)
12:10-12:15
Reshaping oncology through diagnostic precision
Ana Luisa Palacios Acedo, Lunit Inc (online)
12:15-12:25
Discussion and conclusions: Steps towards clinical implementation of AI in Serbia
Jelena Bojović, Office for Information Technologies and e-Government
12:25-13:10
Sponsored symposium
MSD
Integrated Approaches to Improving Cancer Care Outcomes
in Serbia: Prevention, Early Diagnosis, and Treatment as a
Path to Systemic Solutions
Moderator: Marijana Milović Kovačević
Panelists: Bojan Zarić, Ana Cvetanović, Zoran Andrić, Thomas
Hofmarcher
13:10-14:10
Lunch
14:10-16:00
When Cancer Comes Early: New Perspectives on Young-Onset Malignancies
Moderators: Jelena Spasić, Ivana Božović Spasojević
14:10-14:25
Rising Tide: Tackling the Challenge of Early-Onset Cancers in breast cancer
Ivana Božović Spasojević
14:25-14:35
Discussion
14:35-14:50
Rising Tide: Tackling the Challenge of Early-Onset Cancers in lung cancer
Jelena Spasić
14:50-15:00
Discussion
15:00-15:15
Rising Tide: Tackling the Challenge of Early-Onset Cancers in colorectal cancer
Neda Nikolić
15:15-15:25
Discussion
15:25-15:40
Rising Tide: Tackling the Challenge of Early-Onset Cancers in gynecological cancers
Marta Nerone (Switzerland)
15:40-15:50
Discussion
15:50-16:50
Sponsored symposium
Amicus
The CheckMate Series: Redefining Standards in Oncology
Neoadjuvant Immunochemotherapy for NSCLC - Findings from
CheckMate 816 - Bojan Zarić
CheckMate-9LA: Dual Immunotherapy and Chemotherapy in
First-Line NSCLC - Zoran Andrić
1L Urothelium: CheckMate 901 Study Outcomes - Suzana
Matković
CheckMate 214: Transforming First-Line RCC Therapy - Maja
Popović
Opdivo Plus Chemo: Key Findings from CheckMate-649 - Marija
Ristić
16:50-17:00
Coffee break
17:00-18:40
From 3D-CRT, IMRT, and VMAT to Proton and Hadron Therapy:
Shaping the Future of Radiotherapy
Moderators: Marina Nikitović, Tatjana Stanojković
17:00-17:15
Modern radiotherapy - what does the future offer us
Aleksandar Stepanović
17:15-17:30
Advancing Cancer Care Through Particle Therapy
Angelica Facoetti (Italy)
17:30-17:45
The Slovenian proton therapy project
Mark Pleško (Slovenia)
17:45-18:00
Proton therapy - clinical aspects
Jelena Bokun
18:00-18:15
RadExIORSBoost Exploring Individual Radiosensitivity: A Voyage Through RNA and miRNA Universe
Nina Petrović
18:15-18:30
The Role of Tumor-Derived Exosomal miRNAs in the Tumor Microenvironment and Circulating Cell Signaling
Ivan Jovanović
18:30-18:40
Discussion
Hall A
08:00-08:30
Oral presentations of selected abstracts
08:30-09:40
Cancer-Associated Thrombosis: From Mechanisms to Risk Stratification and Clinical Management - Promotion of National Guidelines for CAT
Moderator: Darko Antić
08:30-08:35
Address by a representative of the Ministry of Health
08:35-08:40
Address by a representative of the Serbian Medical Society Academy of Medical Sciences
08:40-08:45
Address by a guideline reviewer
08:45-09:40
Panel discussion
Snežana Bošnjak, Jelena Dimitrijević, Darko Antić, Mirjana Mitrović, Nikica Sabljić, Nikola Pantić
09:40-10:00
Coffee Break
10:00-10:35
HOT TOPIC
National Guidelines for Diagnostics and Treatment of Melanoma –
current possibilities and perspective
Moderators: Ivan Marković, Borislava Nikolin
10:00-10:10
Overview of current recommendations
Suzana Matković
10:10-10:20
Melanoma surgery in the era of modern therapies
Ivan Marković
10:20-10:35
Discussion
10:35-11:20
Sponsored symposium
MSD
Clinical Experiences with Immunotherapy in the Treatment
of Melanoma and Triple-Negative Breast Cancer
Moderators: Ivana Božović Spasojević, Suzana Matković
Panelists: Marina Petronijević, Nemanja Kolović
11:20-11:30
Coffee Break
11:30-13:00
Genetic testing protocols for hereditary breast cancer: Steps toward equal access and consistent implementation of guidelines nationwide
Moderators: Ana Krivokuća, Snežana Šušnjar
11:30-11:40
Hereditary breast cancer in Serbia – prevalence and current testing protocol
Marija Đorđić Crnogorac
11:40-11:50
Indications for panel testing of hereditary breast cancer – new guidelines
Ana Krivokuća
11:50-12:05
Genetic testing for hereditary breast cancer through therapeutic indications (application of new drugs)
Snežana Šušnjar
12:05-12:15
Discussion
12:15-12:30
Experiences with genetic testing of hereditary mutations and plans for implementing new protocols – Novi Sad
Tatjana Ivković Kapicl
12:30-12:45
Experiences with genetic testing of hereditary mutations and plans for implementing new protocols – Niš
Ana Cvetanović
12:45-13:00
Discussion
13:00-14:00
Lunch
14:00-14:50
Endometrial Cancer: From Molecular Classification to Multimodal Therapy
Moderator: Anđela Karaferić
14:00-14:10
The Role of Sentinel Lymph Node Biopsy in Staging and Therapeutic Decision- Making in Endometrial Cancer
Petar Radlović
14:10-14:20
Postoperative Radiotherapy for Endometrial Cancer: New ESGO/ESTRO/ESP Guidelines and Controversies in the Adjuvant Setting
Bojan Todorović
14:20-14:30
Recent Advances in Systemic Therapy for Recurrent and Metastatic Endometrial Cancer: Insights from the DUO-E Trial
Simonida Bobić
14:30-14:50
Panel discussion
Ognjen Živković, Stefan Joksimović, Milana Matović, Mirjana Miković, Katarina Stefanović
14:50-15:00
Coffee Break
15:00-16:00
Cervical Cancer: De-escalation, Innovation, and Integration in Modern Management
Moderator: Marijana Milović Kovačević
15:00-15:10
Surgical De-escalation in Low-Risk Early Cervical Cancer
Bojana Gutić
15:10-15:20
Approaches to the Management of Locally Advanced Cervical Cancer: INTERLACE vs EMBRACE I vs KEYNOTE-A18
Olivera Ivanov
15:20-15:30
Key Insights into Brachytherapy from the EMBRACE II Study
Mirjana Miković
15:30-15:40
Final Overall Survival Analysis from the KEYNOTE-826 Study
Marijana Milović Kovačević
15:40-16:00
Panel discussion
Aleksandar Tomašević, Stefan Joksimović, Ilinka Todorovska, Lidija Pavlović, Irena Conić, Marija Živković
16:00-17:10
Total Body Irradiation (TBI)
Moderator: Tatjana Arsenijević
16:00-16:10
Principles of Hematopoietic Stem Cell Transplantation
Milena Todorović Balint
16:10-16:20
Modern Techniques of TBI
Tatjana Arsenijević
16:20-16:30
Role of the Medical Physicist in Planning and Delivery of TBI
Snežana Voštinić
16:30-16:40
Experience of Institute for Oncology and Radiology of Serbia in Implementing TBI
Aleksandar Stepanović
16:40-16:50
Experience of University Hospital Center Zagreb in Implementing TBI
Lea Galunić Bilić (Croatia)
16:50-17:10
Panel discussion
Milena Todorović Balint, Aleksandar Stepanović, Ivana Mišković
Closing remarks and congress evaluation
